DOPAMINE HCL INJ 4% 40 MG
DOPAMINE HYDROCHLORIDE : 40 MG · DIN 00423823 · INTERNATIONAL MEDICATION SYSTEMS LTD.
Health Canada status: CANCELLED POST MARKET
What is DOPAMINE HCL INJ 4%?
DOPAMINE HCL INJ 4% 40 MG contains DOPAMINE HYDROCHLORIDE : 40 MG. It is listed in the Health Canada Drug Product Database under DIN 00423823, held by INTERNATIONAL MEDICATION SYSTEMS LTD., supplied as LIQUID for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 15-Aug-1997. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00423823 |
|---|---|
| Brand name | DOPAMINE HCL INJ 4% |
| Generic / active ingredient | DOPAMINE HYDROCHLORIDE : 40 MG |
| Manufacturer | INTERNATIONAL MEDICATION SYSTEMS LTD. |
| Strength | 40 MG |
| Dosage form | LIQUID |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | C01CA04 DOPAMINE |
| AHFS class | 12:12.08.08 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 15-Aug-1997 |
| Original market date | 1980-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code C01CA04 DOPAMINE. 3 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| DOPAMINE HCL 0.8MG/ML DEXTROSE 5% INJ USP | 50 MG | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00761850 |
| DOPAMINE HCL 1.6MG/ML DEXTROSE 5% INJ USP | 1.6 MG | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00761826 |
| DOPAMINE HCL 3.2MG/ML DEXTROSE 5% INJ USP | 3.2 MG | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00761834 |
| DOPAMINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION USP | 50 MG | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 00619698 |
| DOPAMINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION USP | 50 MG | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 00619701 |
| DOPAMINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION USP | 50 MG | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 00782394 |
| INTROPIN INJECTION 40MG/ML | 40 MG | SOLUTION | BRISTOL-MYERS SQUIBB CANADA | CANCELLED POST MARKET | DIN 01914014 |
Who else supplies DOPAMINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DOPAMINE appears in 16 registered pack listings across 5 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.